Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
University of Texas Medical Branch, Galveston, Texas, United States
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Local Institution - 0010, Auckland, New Zealand
Local Institution - 0013, Fort Wayne, Indiana, United States
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie, Napoli, Italy
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Gustave Roussy, Villejuif, Val De Marne, France
Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark
Boston Children's Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institite, Boston, Massachusetts, United States
Local Institution, Princeton, New Jersey, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.